Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cambrex Corp (CBM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,350,786
  • Shares Outstanding, K 33,609
  • Annual Sales, $ 532,090 K
  • Annual Income, $ 92,420 K
  • 36-Month Beta 2.45
  • Price/Sales 2.42
  • Price/Cash Flow 9.80
  • Price/Book 1.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.72
  • Growth Rate Est. (year over year) +138,650.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.80 +18.88%
on 02/14/19
45.13 -10.97%
on 02/01/19
-2.59 (-6.06%)
since 01/22/19
3-Month
33.80 +18.88%
on 02/14/19
49.70 -19.15%
on 12/04/18
-7.18 (-15.16%)
since 11/21/18
52-Week
33.80 +18.88%
on 02/14/19
69.43 -42.12%
on 09/28/18
-12.07 (-23.10%)
since 02/22/18

Most Recent Stories

More News
Cambrex (CBM) Surpasses Q4 Earnings Estimates

Cambrex (CBM) delivered earnings and revenue surprises of 2.86% and -15.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

CBM : 40.18 (-0.02%)
Cambrex: 4Q Earnings Snapshot

EAST RUTHERFORD, N.J. (AP) _ Cambrex Corp. (CBM) on Wednesday reported fourth-quarter net income of $1.2 million.

CBM : 40.18 (-0.02%)
Cambrex Reports Fourth Quarter and Full Year 2018 Financial Results

- Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base -

CBM : 40.18 (-0.02%)
Cambrex (CBM) Upgraded to Buy: Here's What You Should Know

Cambrex (CBM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CBM : 40.18 (-0.02%)
Cambrex to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019

Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that fourth quarter...

CBM : 40.18 (-0.02%)
After Yesterday's Decline of 2.62%, Cambrex Corp Offers Investors Better Value

Cambrex Corp (NYSE:CBM) traded in a range yesterday that spanned from a low of $42.29 to a high of $43.22. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $43.26...

CBM : 40.18 (-0.02%)
CBM or ILMN: Which Is the Better Value Stock Right Now?

CBM vs. ILMN: Which Stock Is the Better Value Option?

ILMN : 300.99 (+1.38%)
CBM : 40.18 (-0.02%)
Is Cambrex (CBM) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

CBM : 40.18 (-0.02%)
CBM or ALKS: Which Is the Better Value Stock Right Now?

CBM vs. ALKS: Which Stock Is the Better Value Option?

ALKS : 33.24 (+2.06%)
CBM : 40.18 (-0.02%)
Citigroup, Honeywell and Salesforce surge

NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:

MPC : 65.40 (+1.14%)
C : 64.12 (-0.31%)
CBM : 40.18 (-0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade CBM with:

Business Summary

Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers' small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients...

See More

Key Turning Points

2nd Resistance Point 41.69
1st Resistance Point 40.94
Last Price 40.20
1st Support Level 38.77
2nd Support Level 37.35

See More

52-Week High 69.43
Fibonacci 61.8% 55.82
Fibonacci 50% 51.61
Fibonacci 38.2% 47.41
Last Price 40.20
52-Week Low 33.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar